Ascentage Pharma Group International
ASPHF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.25 | 3.33 | -0.77 | 5.66 |
| FCF Yield | -2.33% | -12.17% | -13.86% | -10.54% |
| EV / EBITDA | -26.30 | -9.63 | -7.76 | -10.05 |
| Quality | ||||
| ROIC | -17.02% | -39.67% | -42.89% | -34.66% |
| Gross Margin | 97.03% | 86.24% | 89.51% | 88.08% |
| Cash Conversion Ratio | 0.28 | 0.78 | 0.74 | 0.77 |
| Growth | ||||
| Revenue 3-Year CAGR | 67.22% | 99.61% | 156.34% | 24.36% |
| Free Cash Flow Growth | 82.67% | 8.67% | 17.58% | -20.96% |
| Safety | ||||
| Net Debt / EBITDA | -1.82 | -0.98 | -0.36 | 0.72 |
| Interest Coverage | -5.74 | -9.08 | -16.74 | -55.77 |
| Efficiency | ||||
| Inventory Turnover | 4.41 | 1.89 | 2.33 | 0.85 |
| Cash Conversion Cycle | -1,034.46 | -432.66 | -1,334.18 | -6,634.91 |